Changes in cytokine production of breast cancer patients treated with interferons

Vivian Barak; Inna Kalickman; Benjamin Nisman; Hanan Farbstein; Zvi G. Fridlender; Lea Baider; Atara Kaplan; Samir Stephanos; Tamar Peretz

doi:10.1006/cyto.1998.0378

Changes in cytokine production of breast cancer patients treated with interferons

Vivian Barak^*, Inna Kalickman, Benjamin Nisman, Hanan Farbstein, Zvi G. Fridlender, Lea Baider, Atara Kaplan, Samir Stephanos, Tamar Peretz

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

A clinical randomized study was performed on advanced breast cancer patients which were treated by interferons (IFN) β and γ in combination with hormonotherapy (Megace or Tamoxifen). Cytokine levels (IL-1β, IL-2, IL-6, TNF-α, IFN-γ) and sIL-2R of individual patients before, during (3 months) and after (6 months) therapy were evaluated and correlated to clinical response according to UICC criteria (responder patients - Partial or Complete Response versus non-responder patients - Stable/Progression). Decreases in IL-1β, IL-6 and sIL-2R were associated with clinical response to therapy versus increases in their levels which corresponded to progression of disease. A significant and dramatic increase in IFN-γ levels was associated with a favourable response to therapy in the IFNs-treated patients, mainly in the group of Tamoxifen. Baseline levels of sIL-2R and of IFN-γ were prognostic of clinical response and were found to be the most sensitive cytokine parameters for defining the clinical utility of the combination of IFNs and hormonotherapy in breast cancer patients.

Original language	English
Pages (from-to)	977-983
Number of pages	7
Journal	Cytokine
Volume	10
Issue number	12
DOIs	https://doi.org/10.1006/cyto.1998.0378
State	Published - Dec 1998
Externally published	Yes

Keywords

Breast cancer
Cytokine receptors
Cytokines
Interferons

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1006/cyto.1998.0378

Cite this

@article{cbf681b071944bc096cfebcd3ae4217b,

title = "Changes in cytokine production of breast cancer patients treated with interferons",

abstract = "A clinical randomized study was performed on advanced breast cancer patients which were treated by interferons (IFN) β and γ in combination with hormonotherapy (Megace or Tamoxifen). Cytokine levels (IL-1β, IL-2, IL-6, TNF-α, IFN-γ) and sIL-2R of individual patients before, during (3 months) and after (6 months) therapy were evaluated and correlated to clinical response according to UICC criteria (responder patients - Partial or Complete Response versus non-responder patients - Stable/Progression). Decreases in IL-1β, IL-6 and sIL-2R were associated with clinical response to therapy versus increases in their levels which corresponded to progression of disease. A significant and dramatic increase in IFN-γ levels was associated with a favourable response to therapy in the IFNs-treated patients, mainly in the group of Tamoxifen. Baseline levels of sIL-2R and of IFN-γ were prognostic of clinical response and were found to be the most sensitive cytokine parameters for defining the clinical utility of the combination of IFNs and hormonotherapy in breast cancer patients.",

keywords = "Breast cancer, Cytokine receptors, Cytokines, Interferons",

author = "Vivian Barak and Inna Kalickman and Benjamin Nisman and Hanan Farbstein and Fridlender, {Zvi G.} and Lea Baider and Atara Kaplan and Samir Stephanos and Tamar Peretz",

year = "1998",

month = dec,

doi = "10.1006/cyto.1998.0378",

language = "אנגלית",

volume = "10",

pages = "977--983",

journal = "Cytokine",

issn = "1043-4666",

publisher = "Academic Press Inc.",

number = "12",

}

TY - JOUR

T1 - Changes in cytokine production of breast cancer patients treated with interferons

AU - Barak, Vivian

AU - Kalickman, Inna

AU - Nisman, Benjamin

AU - Farbstein, Hanan

AU - Fridlender, Zvi G.

AU - Baider, Lea

AU - Kaplan, Atara

AU - Stephanos, Samir

AU - Peretz, Tamar

PY - 1998/12

Y1 - 1998/12

N2 - A clinical randomized study was performed on advanced breast cancer patients which were treated by interferons (IFN) β and γ in combination with hormonotherapy (Megace or Tamoxifen). Cytokine levels (IL-1β, IL-2, IL-6, TNF-α, IFN-γ) and sIL-2R of individual patients before, during (3 months) and after (6 months) therapy were evaluated and correlated to clinical response according to UICC criteria (responder patients - Partial or Complete Response versus non-responder patients - Stable/Progression). Decreases in IL-1β, IL-6 and sIL-2R were associated with clinical response to therapy versus increases in their levels which corresponded to progression of disease. A significant and dramatic increase in IFN-γ levels was associated with a favourable response to therapy in the IFNs-treated patients, mainly in the group of Tamoxifen. Baseline levels of sIL-2R and of IFN-γ were prognostic of clinical response and were found to be the most sensitive cytokine parameters for defining the clinical utility of the combination of IFNs and hormonotherapy in breast cancer patients.

AB - A clinical randomized study was performed on advanced breast cancer patients which were treated by interferons (IFN) β and γ in combination with hormonotherapy (Megace or Tamoxifen). Cytokine levels (IL-1β, IL-2, IL-6, TNF-α, IFN-γ) and sIL-2R of individual patients before, during (3 months) and after (6 months) therapy were evaluated and correlated to clinical response according to UICC criteria (responder patients - Partial or Complete Response versus non-responder patients - Stable/Progression). Decreases in IL-1β, IL-6 and sIL-2R were associated with clinical response to therapy versus increases in their levels which corresponded to progression of disease. A significant and dramatic increase in IFN-γ levels was associated with a favourable response to therapy in the IFNs-treated patients, mainly in the group of Tamoxifen. Baseline levels of sIL-2R and of IFN-γ were prognostic of clinical response and were found to be the most sensitive cytokine parameters for defining the clinical utility of the combination of IFNs and hormonotherapy in breast cancer patients.

KW - Breast cancer

KW - Cytokine receptors

KW - Cytokines

KW - Interferons

UR - http://www.scopus.com/inward/record.url?scp=0032468321&partnerID=8YFLogxK

U2 - 10.1006/cyto.1998.0378

DO - 10.1006/cyto.1998.0378

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 10049522

AN - SCOPUS:0032468321

SN - 1043-4666

VL - 10

SP - 977

EP - 983

JO - Cytokine

JF - Cytokine

IS - 12

ER -

Changes in cytokine production of breast cancer patients treated with interferons

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this